Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BPMUFNASDAQ:BSTCNASDAQ:CPRXNASDAQ:CRBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$44.45$41.11$38.60▼$44.45$526.79M0.655 shsN/ABSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ACPRXCatalyst Pharmaceuticals$15.34-4.1%$15.38$11.09▼$17.78$1.89B0.891.00 million shs1.49 million shsCRBPCorbus Pharmaceuticals$36.53-1.7%$34.93$3.03▼$49.87$390.45M2.46231,871 shs128,015 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+9.08%+8.41%-14.52%BSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%CPRXCatalyst Pharmaceuticals-4.13%-2.97%-6.41%+5.36%-11.48%CRBPCorbus Pharmaceuticals-1.70%-8.68%-14.57%+418.16%+262.76%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACPRXCatalyst Pharmaceuticals4.9877 of 5 stars4.51.00.03.92.93.34.4CRBPCorbus Pharmaceuticals4.4276 of 5 stars3.53.00.04.72.83.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea PharmaceuticaN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/ACPRXCatalyst Pharmaceuticals3.00Buy$26.4372.29% UpsideCRBPCorbus Pharmaceuticals3.00Buy$52.0042.35% UpsideCurrent Analyst RatingsLatest CPRX, BPMUF, CRBP, and BSTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024CPRXCatalyst PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$29.003/22/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/7/2024CPRXCatalyst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.003/1/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $34.003/1/2024CPRXCatalyst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29BSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81CPRXCatalyst Pharmaceuticals$398.20M4.55$1.97 per share7.78$3.30 per share4.65CRBPCorbus Pharmaceuticals$880K436.28N/AN/A($1.56) per share-23.42Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/ABSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ACPRXCatalyst Pharmaceuticals$71.41M$0.6125.157.040.8817.93%26.56%22.13%5/8/2024 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)Latest CPRX, BPMUF, CRBP, and BSTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/28/2024Q4 2023CPRXCatalyst Pharmaceuticals$0.45$0.49+$0.04$0.67$105.78 million$110.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea PharmaceuticaN/A3.202.64BSTCBioSpecifics TechnologiesN/A66.2466.24CPRXCatalyst PharmaceuticalsN/A2.882.68CRBPCorbus PharmaceuticalsN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ABSTCBioSpecifics Technologies60.34%CPRXCatalyst Pharmaceuticals79.22%CRBPCorbus Pharmaceuticals64.64%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ABSTCBioSpecifics Technologies15.70%CPRXCatalyst Pharmaceuticals12.10%CRBPCorbus Pharmaceuticals4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableCPRXCatalyst Pharmaceuticals167118.01 million103.73 millionOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableCPRX, BPMUF, CRBP, and BSTC HeadlinesSourceHeadlineHere's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strengthmsn.com - April 16 at 1:09 PMShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expands By 17.8%americanbankingnews.com - April 16 at 5:10 AMCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Updatemarketbeat.com - April 14 at 2:55 PMCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Above 50 Day Moving Average of $33.45americanbankingnews.com - April 12 at 3:28 AMCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADCglobenewswire.com - April 2 at 8:00 AMShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expands By 560.9%marketbeat.com - March 27 at 3:43 PMCRBP Factor-Based Stock Analysisnasdaq.com - March 22 at 8:18 PMBuffett Can't Get Enough of This Stock, Plus Other Insider Buying247wallst.com - March 17 at 9:10 AMWhat Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'zacks.com - March 15 at 9:51 AMCorbus Pharmaceuticals files for $300M mixed shelf offeringmsn.com - March 13 at 8:20 PMCorbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 12 at 1:05 PMCorbus Pharmaceuticals: Q4 Earnings Snapshotseattlepi.com - March 12 at 1:05 PMCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 12 at 8:00 AMInsider Buying: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Buys 250,000 Shares of Stockinsidertrades.com - March 12 at 4:34 AMCRBP Apr 2024 25.000 putfinance.yahoo.com - March 11 at 4:25 PMCRBP Mar 2024 45.000 putfinance.yahoo.com - March 11 at 6:24 AMCRBP Jun 2024 50.000 putfinance.yahoo.com - March 10 at 10:11 PMCRBP Jun 2024 50.000 callfinance.yahoo.com - March 10 at 10:11 PMAll Three of Our Analysts Agreeinvestorplace.com - March 8 at 8:02 PMCRBP Mar 2024 40.000 callfinance.yahoo.com - March 7 at 3:44 PMCorbus Pharmaceuticals just upgraded at Jefferies, here's whyrealmoney.thestreet.com - March 6 at 6:26 PMCorbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summitglobenewswire.com - March 6 at 8:00 AMCorbus Pharmaceuticals Names Dominic Smethurst CMOmarkets.businessinsider.com - February 28 at 4:39 PMCorbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officerglobenewswire.com - February 28 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBasilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.BioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Catalyst PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.